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ABSTRACT 
 
Aims: To estimate the effectiveness of pregnancy smoking cessation support delivered by 
SMS text message and key parameters needed to plan a definitive trial. 
Design: Multicentre, parallel-group, single-blinded, individual randomised controlled trial 
Setting: 16 antenatal clinics in England. 
Participants: 407 participants were randomised to the intervention (n=203) or usual care 
(n=204). Eligible women were <25 weeks gestation, smoked at least 1 daily cigarette (> 5 
pre-pregnancy), were able to receive and understand English SMS texts and were not 
already using text-based cessation support. 
Intervention: All participants received a smoking cessation leaflet; intervention 
participants also received a 12-week programme of individually-tailored, automated, 
interactive, self-help smoking cessation text messages (MiQuit). 
Outcome Measurements: Seven smoking outcomes including validated continuous 
abstinence from 4 weeks post-randomisation until 36 weeks gestation, design parameters 
for a future trial and cost-per-quitter. 
Findings: Using the validated, continuous abstinence outcome, 5.4% (11/203) of MiQuit 
participants were abstinent versus 2.0% (4/204) of usual care participants (odds ratio [OR] 
2.7, 95% confidence interval [CI] 0.93 to 9.35). The Bayes Factor for this outcome was 
2.23. Completeness of follow up at 36 weeks gestation was similar in both groups; 
provision of self-report smoking data was 64% (MiQuit) and 65% (usual care) and 
abstinence validation rates were 56% (MiQuit) and 61% (usual care). The incremental 
cost-per-quitter was £133.53 (95% CI -£395.78 to £843.62). 
Conclusions: There was some evidence, though not conclusive, that a text messaging 
programme may increase cessation rates in pregnant smokers when provided alongside 
routine NHS cessation care. 
 
Keywords: Smoking cessation, pregnancy, self-help, randomised controlled trial, SMS 
text messaging, mHealth 
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INTRODUCTION 
Smoking in pregnancy is strongly associated with pregnancy complications including 
miscarriage,1 spontaneous preterm birth,2 small for gestational age,2 and stillbirth.3 4 
Smoking in pregnancy also perpetuates health inequalities; rates are around five times 
higher in the most deprived women compared with the least deprived5-7 and children born to 
smokers have an increased risk of becoming smokers themselves.8 9 Systematic review 
evidence shows that behavioural smoking cessation interventions reduce the risks of 
preterm birth and low birthweight by around 18%.10 
 
Structured self-help support helps pregnant smokers to stop.11 12 Mobile phone text 
messaging is a simple way of providing self-help support and is effective for non-pregnant 
smokers.13 However, many aspects of „generic‟ text messaging cessation systems are 
unlikely to be appropriate in pregnancy. Available generic programmes make no mention of 
pregnancy,13 which for most pregnant smokers is the main reason they try quitting,14 and 
effective behavioural support for pregnant smokers is typically strongly pregnancy-
orientated.10 Consequently, pregnant smokers may find much of the behavioural support 
delivered by generic programmes irrelevant, reducing its impact and perhaps even being 
counterproductive.15 Even more importantly, available „generic‟ programmes provide some 
advice and support that potentially could be harmful in pregnancy. For example, use of 
nicotine replacement therapy (NRT) is encouraged without consideration of pregnancy-
specific risks, and generic advice on keeping fit and weight gain after quitting are quite 
different from what might be appropriate in pregnancy. 
 
To maximise the potential of self-help support for helping pregnant smokers to stop, we have 
developed an individually-tailored SMS text messaging intervention specifically for pregnant 
smokers, called MiQuit. This process followed the Medical Research Council framework for 
developing and evaluating complex interventions16 and was informed by extensive 
qualitative work with pregnant smokers.17 MiQuit can be used by all pregnant smokers as the 
support it provides is tailored to a woman‟s level of motivation to quit. A randomised 
controlled trial (RCT) (N=207) demonstrated that randomisation to MiQuit or routine care is 
feasible, that women find MiQuit highly acceptable and that MiQuit is likely to encourage 
cessation until at least mid-pregnancy.18 This feasibility trial provided the best available 
estimate for MiQuit efficacy, albeit for a relatively brief cessation period; we believed 
cessation at the end of pregnancy would be a more appropriate outcome for a definitive trial 
as this would result in maximal benefits for the fetus. As MiQuit is a cheap intervention with 
potential for wide dissemination, we anticipated that even a 1-2% absolute effect on smoking 
cessation in pregnancy could prove clinically important and cost effective and the imprecise 
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efficacy estimate we had obtained suggested that an impact of this size was potentially 
attainable. Consequently, we planned a full trial to detect such an effect on smoking 
cessation until the end of pregnancy and estimated this could require 3-4000 participants. 
This large, pilot RCT was conducted to investigate the feasibility of undertaking a much 
larger multi-centre RCT in UK National Health Service (NHS) settings to determine whether 
or not MiQuit can impact on cessation throughout pregnancy. The current trial would also 
provide estimates of effectiveness and cost effectiveness, with the latter enabling 
comparisons with other cessation interventions.  
 
 
 
METHODS 
Design 
This was a multicentre, two-arm, parallel group, single blind, individually randomised 
controlled trial.  
 
Study population 
Participants were recruited from 16 English NHS hospital antenatal clinics between February 
and September 2014. They were aged 16 and over, less than 25 weeks pregnant, had 
smoked at least five cigarettes daily before pregnancy and at least one per day at enrolment, 
able to understand written English and owned a mobile phone with text messaging 
functionality. Participants already using text message-based smoking cessation support 
were excluded.  
 
Study protocol and interventions 
The study protocol was approved by Nottingham 1 Research Ethics Committee 
(Ref.:13/EM/0427) and subsequently published.19  
 
Usual care 
Participants were given a standard NHS booklet on smoking cessation for mums-to-be 
(appendix 1) and could access smoking cessation information, advice or support for stopping 
smoking offered as part of routine antenatal care. 
 
Intervention  
Two days after enrolment, in addition to the booklet and usual care, intervention participants 
started to receive MiQuit; an automated 12-week advice and support programme for quitting 
smoking in pregnancy delivered by SMS text message. MiQuit objectives are informed by 
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Social Cognitive Theory,20 Perspectives on Change Theory (Borland, 2000, unpublished 
work), the Elaboration Likelihood Model of Persuasion21 and several additional cognitive 
determinants of quitting smoking in pregnancy.18 It uses 14 participant characteristics to 
individually-tailor support.22 Tailoring characteristics include gestation, motivation to quit, the 
hardest situation to avoid smoking, cessation self-efficacy, cigarette dependence and 
partner‟s smoking status. 'Push' support (i.e. automated support sent to participants‟ phones) 
is delivered according to a delivery schedule (0, 1 or 2 daily texts). Push message frequency 
is highest in the first 4 weeks. Push support includes motivational messages, advice about 
quit attempt preparation, managing cravings and withdrawal, dealing with trigger situations 
and preventing lapses, information about fetal development and how smoking affects this 
(see appendix 2 for example messages and tailoring variables). Users can alter support 
frequency by texting the keywords MORE or LESS, and are encouraged to set and send a 
quit date to MiQuit to enable them to receive additional support orientated around when their 
quit attempt begins. At 3 and 7 weeks into the programme, users are asked to respond to 
texts asking about smoking in the previous 3 days, so that subsequent support is further 
tailored to smoking behaviour.22 Additionally, system users can 'pull' on-demand support for 
combatting cravings or temptation to smoke by texting HELP and seek advice on returning to 
abstinence after a lapse by texting SLIP. Alternatively, texting QUIZ provides a multiple 
choice message trivia game designed to distract users from smoking. Support can be 
discontinued by texting STOP. More detailed information about the development and 
structure of the intervention can be found elsewhere18 22 
 
Enrolment, randomisation and blinding  
Research midwives (RMs) identified potential participants in antenatal clinics via their clinic 
notes or a screening questionnaire, and interested women were provided with participant 
information sheets. RMs sought written consent, but if time was insufficient, contact details 
were requested instead and verbal consent was sought later in a phone call from the RM or 
a researcher from the trial coordination team. Next, baseline data were collected and, after 
this was entered onto a web-based database, participants were individually randomised to 
usual care or the MiQuit intervention in a 1:1 ratio using the Nottingham Clinical Trials Unit 
web-based system with both the RM or researcher and the participant remaining masked to 
allocation. Randomisation used a computer generated pseudo-random code with random 
permuted blocks of randomly varying size, and stratification was by study site and gestation 
(<16 weeks vs. ≥16 weeks). Following randomisation, unblinded trial team members sent 
arm-specific information packs to participants, which included the usual care booklet. Those 
dispatching packs were not involved in collecting follow-up data. Trial staff involved in follow-
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up remained unaware of participants‟ treatments until questions on the intervention were 
asked at the end of the study, after smoking outcome data had been collected.  
 
 
Data collection 
Baseline data included contact details, age, highest qualification, postcode to enable 
matching to Index of Multiple Deprivation (IMD) scores,23 ethnicity (based on UK Census 
categories), gestation, pre-pregnancy smoking rate, heaviness of smoking index,24 strength 
and frequency of urges to smoke,25 whether a quit date had been set, intention to quit,18 
number of births beyond 24 weeks, partner‟s (significant other‟s) smoking status and health 
status using EQ-5D.26  
 
Four weeks after randomisation participants were contacted to complete a questionnaire 
assessing smoking status over the past 7 days; we used text messages to notify them to 
expect a telephone call and if after several attempts the call was unsuccessful, we posted 
and emailed a link to the questionnaire. At 36 weeks gestation participants were similarly 
contacted and asked about smoking behaviour since 4 weeks post-randomisation and in the 
past 7 days, quit attempts lasting at least 24 hours and use of smoking cessation support. 
MiQuit arm participants were also asked their views on the intervention. Where 7-day 
complete abstinence from smoking was reported, we immediately attempted to 
biochemically validate this with exhaled-breath Carbon Monoxide (CO) readings and/or 
saliva samples tested for cotinine, with samples or readings collected at hospital or home 
visits. If face-to-face collection was not successful, postal saliva sample packs were used. 
Before samples were donated, participants were asked either verbally or by questionnaire 
about smoking status and use of nicotine replacement therapies (NRT) or e-cigarettes.  
 
To encourage engagement, participants received a £5 shopping voucher for providing data 
at each of the first three contacts (i.e. £15 maximum); a £10 voucher was also provided after 
validation visits. Participants were informed of how to withdraw from data collection via 
postcard, telephone, text, or email. 
 
Outcomes 
Future trial design parameters 
We monitored monthly rates of recruitment, outcome ascertainment rates, and estimated the 
validated abstinence rate in both trial arms combined. We aimed to enrol 400 participants in 
12 months. The key smoking outcome for a future trial is described below (#1). 
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Smoking 
Smoking measures were: 1) self-reported abstinence from 4 weeks post-randomisation 
until late pregnancy collected at late pregnancy follow up (approximately 36 weeks 
gestation), with no more than 5 cigarettes in total between the two time points,27 
biochemically validated at the later time; 2) as 1 but self-report only; 3) self-reported 7-day 
point prevalence abstinence at late pregnancy; 4) as 3 but biochemically validated; 5) self-
reported 7-day point prevalence abstinence at 4 weeks post-randomisation; 6) self-
reported 7-day point prevalence abstinence at both 4 weeks post-randomisation and late 
pregnancy; 7) as 6 but biochemically validated in late pregnancy.  
 
We stated a priori that we anticipated that outcome #1, continuous abstinence from 4 weeks 
post-randomisation until 36 weeks gestation, would be most appropriate for a future RCT to 
definitively assess MiQuit efficacy.19 We had concerns about the viability of using this 
outcome, so a key objective was to ascertain its feasibility of measurement. Where 
participants reported abstinence but were using NRT or e-cigarettes, CO readings alone 
were used for validation (cut point of <9 ppm). Otherwise, a saliva cotinine reading of <10 
ng/ml was also required.28 Where data from only one validation method were available, a 
value below the relevant cut-point was considered sufficient. Saliva was analysed by ABS 
Laboratories Ltd, Hertfordshire.   
 
Economic 
As the usual care and intervention groups both had access to standard NHS smoking 
cessation and antenatal care, it was assumed that both groups had equal cost, therefore the 
only additional cost would be for delivering MiQuit. Costs included were the text messages 
and the annual running cost. These were based on historical costs incurred. Costs were 
calculated at 2014-2015 price per year from a NHS and Personal Social Services 
perspective. 
 
Sample size 
The sample size was justified primarily on the basis of how precisely key parameters for the 
design of a definitive RCT could be estimated. With 400 participants (200 per group), we 
could estimate the overall recruitment rate to within +/-1%, outcome ascertainment rates per 
treatment group to within +/-4%, and combined quit rates for both groups to within +/-3%. 
Precision estimates for detecting between-group differences in quit rates were calculated for 
ranges of treatment effects (i.e. odds ratio [OR]) and usual care group quit rates;19 for 
example, these showed that if a 5% usual care group quit rate occurred in late pregnancy, 
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with 400 participants the trial would estimate an OR of 1.8 (as noted in a previous review)12 
with 80% confidence intervals (CIs) of 1.06 to 3.05).19 
 
Statistical analysis 
A statistical analysis plan was agreed with the Trial Steering Committee and published with 
the trial protocol.19 Recruitment and outcome ascertainment rates were estimated with 95% 
CIs. For each treatment group, and for both groups combined, abstinence rates for each 
outcome were estimated with 95% Wilson CIs. Chi-squared tests (Fisher‟s exact tests in 
cases with small expected frequencies) were performed to assess the association between 
smoking outcomes and treatment group. Firth (penalised) logistic regression models29 were 
then used to estimate odds ratios with 95% profile CIs30 to compare smoking outcomes 
between treatment groups, adjusting for factors used to stratify the randomisation via their 
inclusion as fixed covariates in each model (trial site, gestation at randomisation). Three 
additional models for all seven smoking outcomes were carried out, each adjusting for one of 
three baseline variables commonly associated with smoking in pregnancy (heaviness of 
smoking, partner‟s smoking status and education),31 32 with likelihood ratio tests assessing 
whether these improved model prediction. Where convergence of a model could not be 
achieved due to low event rates within small centre sites, these centres were merged to 
overcome the issue. 
 
An intention-to-treat (ITT) analysis was used, with all participants analysed within the 
treatment group to which they were randomised and, where missing outcome data, were 
assumed smoking.27 Participants who withdrew from the study due to miscarriage/stillbirth 
were included in the analyses and classed as smoking. Where validation of abstinence was 
required, participants not providing a breath or saliva sample were classed as smoking. 
Complete case sensitivity analyses were performed on all smoking outcomes.  
 
The number of quit attempts since baseline was compared between groups using a Mann-
Whitney U test. Participants‟ views on the MiQuit intervention were reported using 
percentages with 95% Wilson score CIs. Analyses were carried out in Stata, Version 12. 
 
After undertaking the planned analyses, we decided to generate a Bayes Factor from 
smoking outcome #1, using an online calculator33 with an expected effect size of OR 1.83 
taken from a relevant systematic review.12 We used a conservative approach for estimation 
using a half normal distribution, where the mode at 0 indicated no intervention effect, and the 
standard deviation equal to the expected effect size. 
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Economic analysis 
The main outcome was the incremental cost per additional quitter, calculated by dividing 
the average incremental cost per participant by the number of additional quitters derived 
from smoking outcome #1. Confidence intervals were generated using bootstrapping with 
1,000 iterations.34  
 
 
RESULTS 
Over 7 months, we assessed 1181 pregnant smokers for eligibility and 407 were recruited 
into the study; 203 were randomised to MiQuit and 204 to usual care. There was marked 
variation in recruitment between the 16 sites (median 12 participants, IQR 34), with one 
recruiting no participants. Figure 1 shows participant flow and reasons for exclusion. At 4 
weeks, 295 (72%) participants provided smoking outcome data (68% MiQuit, 77% usual 
care). Further attrition in late-pregnancy was fairly minimal, with 261 (64%) participants 
providing these outcome data (64% MiQuit, 65% usual care). 230 (57%) provided smoking 
outcome data at both time points (55% MiQuit, 58% usual care) and 254 (62%) gave data 
used for smoking outcome #1 on abstinence between 4 weeks and late pregnancy (61% 
MiQuit, 64% usual care). We obtained validation samples for 37/64 (58%) of participants 
who reported abstinence at 36 weeks gestation (56% MiQuit, 61% usual care); with two 
(3.1%) and 15 (23%) participants providing only CO or cotinine readings respectively. 
 
Table 1 shows baseline participant characteristics by trial arm; mean age was 26.5 (SD 5.7) 
years, 92% were White, mean gestation at enrolment was 14.7 (SD 4.4) weeks, and 60% 
reported smoking within 30 minutes of waking. 74% were very or extremely determined to 
stop smoking and 40% felt very or extremely confident in stopping until their baby was born. 
Participants‟ characteristics were similar in both groups apart from that women randomised 
into the usual care group were more likely to reside in the most deprived (e.g. lower income) 
areas and have a non-smoking partner. 
 
 
Smoking outcomes 
Table 2 shows cessation rates across and within treatment groups and provides estimates 
for MiQuit‟s effects. For smoking outcome #1, 15 participants were classified as abstinent; 
11/203 (5.4%) were in the MiQuit group and 4/204 (2.0%) in the usual care group (adjusted 
OR 2.70, 95% CI 0.93 - 9.35). Estimated treatment effects for the remaining smoking 
outcomes also favoured MiQuit aiding smoking cessation, with ORs ranging from 1.03 to 
3.28; those for self-reported abstinence at both 4 weeks post-randomisation and in late 
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pregnancy (smoking outcome #6) reached statistical significance. Adjusting for heaviness of 
smoking, partner‟s smoking status and education did not result in any meaningful changes to 
the findings (see supplementary Table S1). In a sensitivity analysis based on women with 
complete outcome data, the ORs were increased for six out of the seven smoking outcomes, 
including outcome #1 (OR 3.11, 95% CI 1.05 to 10.80) (Table S2). The number of quit 
attempts between baseline and late pregnancy did not differ significantly between treatment 
groups (MiQuit median 2 [IQR 1,3], N=124; usual care median 1 [IQR 0,3], N=130; Mann-
Whitney U p=0.118). The Bayes Factor for outcome #1 was 2.23, meaning that the 
hypothesis that MiQuit is effective is more than twice as likely to be correct than the 
hypothesis that it is not effective. This represents „anecdotal evidence‟ for MiQuit having an 
intervention effect.35 
 
Use of NHS cessation support 
Overall use of „non-trial‟ cessation support was similar in both arms (Table 3). When 
examining specific types of support, midwife discussion of smoking was reported by notably 
more usual care participants.  
 
Participant evaluations of MiQuit 
Among all MiQuit participants, 27 (13%) discontinued support early (mean days into 
programme 24.1, SD 15.7) having texted STOP and 13 (6.4%) changed their message 
frequency to “less”, 11 (5.4%) to “more”, and 1 (0.5%) to “less” followed by “more”. Among 
those at late-pregnancy follow-up who answered the relevant questions, 3/123 (2.4%) 
reported receiving no text messages and, of the remaining 120, 97 (81%) reported reading 
all messages at least once. Messages relating to fetal development were most frequently 
rated (by 35%) as the most helpful. Table 4 shows that 62% rated the text messages as 
quite or extremely helpful but 14% considered them annoying. 81% would either „probably' 
or „definitely‟ recommend MiQuit support to a friend or relative.  
 
 
Economic analysis 
The per-participant cost of sending MiQuit texts was estimated to be £2.95; a mean of 84.1 
texts per participant at 3.5p per text. The annual running cost of delivering MiQuit was £339 
(£1.67 per participant) and included a virtual reply number (£99) and server/web hosting 
including domain name (£240). Thus, the total per-participant MiQuit cost was £4.62. From 
Table 2, row 1, the relevant incremental quit rate estimate was 3.46%, giving an incremental 
cost per additional quitter of £133.53 (95% CI -£395.78 to £843.62). The probability of MiQuit 
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being cost-effective was 96.5% if a decision maker was willing to pay £10,000 to gain an 
additional quitter. 
 
 
DISCUSSION 
Statement of principal findings 
This trial demonstrates the feasibility of recruiting pregnant smokers from multiple UK 
hospital antenatal settings to a trial of a text message cessation support intervention; we met 
our recruitment target 5 months earlier than expected. We also found that it was feasible to 
measure smoking cessation in participants who were not expected to set a quit date using a 
stringent outcome measure. Using this outcome, we found that 5.4% of women in the MiQuit 
group stopped smoking during pregnancy and 2.0% did in the control group and this almost 
reached statistical significance; it is likely, when tested on a larger scale, that MiQuit will 
prove to be both effective and cost effective for promoting smoking cessation throughout 
pregnancy.  
 
Findings in context 
The efficacy estimate provided using outcome #1 data suggests that, compared with usual 
care, MiQuit may almost triple the odds of sustained smoking cessation, but this has limited 
precision. However, it is the best estimate yet produced for the likely efficacy of text 
messaging used for smoking cessation in pregnancy. It is also of a similar magnitude to 
efficacy estimates derived from „definitive‟ trials of similar interventions used by non-
pregnant smokers36 37 and to that from a smaller MiQuit trial.18 Additionally, our estimate for 
the likely cost-effectiveness of the intervention is encouraging; compared with other 
cessation interventions a cost-per-quitter of £134 is low. For example, although financial 
incentives for smoking cessation in pregnancy are highly effective38 and cost-effective,39 
their cost-per-quitter is almost 10 times higher (£1,127). Similarly, MiQuit's cost-efficacy 
compares favourably with that of cessation support delivered by traditional UK smoking 
cessation services; the „cost-per-person-setting-a-quit-date‟ within such services has 
recently been estimated as £202.40 However, as only 34% of those setting a quit date 
achieve longer-term abstinence, the cost-per-quitter,41 inflated accordingly, is probably 
closer to £600. Although the trial did not include a formal cost-utility analysis, it is highly likely 
that, if cessation is maintained in the longer term, the calculated „cost-per-quitter‟ will 
translate into longer-term cost effectiveness. One can assume that „quitters‟ gain 1.94 
Quality-Adjusted Life Years (QALYs) across their lifetime,42 43 so by multiplying this value by 
the seven additional quitters generated by MiQuit the incremental QALYs would be 13.58, 
making the incremental cost per additional QALY £69.06 – even after inflating this figure to 
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take into account relapse to smoking,44 this would remain securely within most accepted 
cost-effectiveness benchmarks. Finally, it is noteworthy that the „non-text-message‟ costs of 
MiQuit are fixed and so „per-user‟ costs fall as the numbers using the intervention increase. 
For example, if MiQuit was used by 2000 pregnant smokers annually, per-user „non-text-
message‟ costs would be around 20p, reducing the incremental cost per additional quitter to 
approximately £91.  
 
Importantly, systems such as MiQuit could be particularly useful for the high proportion of 
pregnant smokers who currently do not access „traditional‟ methods of support.45 46 For 
example, in the UK around 83% of pregnant smokers do not use support offered46 but, if 
encouraged, many of these may use text support. 
 
Strengths and limitations of the study 
A limitation is that this RCT did not have a specified primary outcome; however, although 
multiple cessation outcomes were used, we indicated a priori which was anticipated to be 
the most appropriate as a primary outcome (outcome #1).19 Consequently, as we 
demonstrated that outcome #1 was feasible to measure, it is reasonable to use these data to 
represent MiQuit‟s likely treatment effect. However, caveats to the interpretation of non-
primary RCT outcomes still apply. Additionally, completeness of follow up and biochemical 
validation rates were not optimal, potentially reducing statistical power. However, we 
conservatively assumed that women lost to follow up were still smoking27 and outcome 
ascertainment rates were slightly higher in the usual care group; both factors would tend to 
attenuate rather than inflate the observed intervention effect. Consistent with this 
observation, the complete case analyses showed stronger intervention effects for most 
smoking outcomes, including a statistically significant between-group difference for 
cessation outcome #1. As with many RCTs, a further limitation is the unknown 
generalisability of findings to all pregnant smokers. We did not systematically record data on 
the numbers or characteristics of pregnant smokers attending hospital units during trial 
recruitment, so we cannot say how representative the trial sample is; although, based on 
socio-economic characteristics and smoking rates at pre-pregnancy and baseline, the 
sample was generally representative of women who smoke in pregnancy and are recruited 
to trials.10 Ease of recruitment in antenatal care settings suggests there is a substantial 
cohort of pregnant smokers who would be likely to use MiQuit if offered this as part of routine 
care. Moreover, we have already shown that 3-4% of pregnant smokers will initiate MiQuit 
after receiving a one-page leaflet advertising this in their „antenatal booking pack‟.22 
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A key strength is that this is the largest RCT to investigate the efficacy of text message-
based, self-help cessation support which is appropriate for and can be safely followed by 
pregnant smokers. The study was conducted to the highest RCT standards; it employed 
remote randomisation, those enrolling participants were blind to treatment allocations and 
abstinence was biochemically validated. Additionally, researchers collecting outcome data 
were, where possible, blind to treatment allocations, so outcome ascertainment bias was 
minimised. Intervention fidelity was high, 98% of MiQuit recipients recalled receiving text 
message support, and similarities between adjusted and unadjusted analysis models imply 
that chance differences in groups‟ baseline characteristics do not explain findings. Similarly, 
it seems unlikely that use of other „non-trial‟ cessation support explains findings; use of such 
support was very similar in both groups except that usual care group women were more 
likely to report having discussed smoking with a midwife. Such support would be expected to 
increase cessation in the usual care group, reducing the apparent efficacy of MiQuit. Overall, 
therefore, it seems likely that differences between groups‟ smoking rates are due to MiQuit 
and not to other factors. 
 
Conclusions 
MiQuit is likely to be an effective smoking cessation intervention and further evaluative 
research is needed. If further research is confirmatory, pregnancy-orientated text message 
systems like MiQuit could quickly and cheaply be made available alongside other first-line 
support options to help pregnant smokers to stop.  
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Table 1 Baseline characteristics by treatment group 
 
 MiQuit
†
 
(N=203) 
Usual Care
†
 
(N=204) 
Age (years)  
Mean[SD] 
Median[1
st
 Q, 3
rd
 Q] 
Min, max 
 
26.6 (5.7) 
25.7 (22.1, 
30.8) 
16.9, 40.0 
 
26.4 (5.7) 
25.8 (21.9, 29.7) 
16.6, 41.3 
Highest qualification  
No formal qualification  
GCSE or similar  
A level or similar  
Degree or similar  
Declined to answer  
 
37 (18.2) 
117 (57.6) 
32 (15.8) 
16 (7.9) 
1 (0.5) 
 
44 (21.6) 
106 (52.0) 
37 (18.1) 
13 (6.4) 
4 (2.0) 
IMD score* 
Quintile 1 
Quintile 2 
Quintile 3 
Quintile 4 
Quintile 5 
missing 
 
13 (6.4) 
16 (7.9) 
22 (10.8) 
53 (26.1) 
92 (45.3) 
7 (3.5) 
 
6 (2.9) 
13 (6.4) 
21 (10.3) 
50 (24.5) 
108 (52.9) 
6 (2.9) 
Ethnicity  
White  
Indian  
Pakistani  
Bangladeshi  
Black Caribbean  
Black African  
Black(other) 
Chinese  
Other Asian (non-Chinese) 
Mixed  
Not given 
 
188 (92.6) 
0 (0) 
3 (1.5) 
0 (0) 
1 (0.5) 
2 (1.0) 
1 (0.5) 
0 (0) 
1 (0.5) 
6 (3.0) 
1 (0.5) 
 
185 (90.7) 
0 (0) 
2 (1.0) 
0 (0) 
4 (2.0) 
1 (0.5) 
1 (0.5) 
0 (0) 
0 (0) 
11 (5.4) 
0 (0) 
Gestation at randomisation (weeks) 
Mean[SD] 
 Median[1
st
 Q, 3
rd
 Q] 
 Min, max 
 
14.6 (4.2) 
13 (12, 19) 
4, 23 
 
14.7 (4.5) 
13 (12, 20) 
3, 24 
Cigarettes per day before pregnancy  
Mean[SD] 
 Median[1
st
 Q, 3
rd
 Q] 
 Min, max 
 
15.7 (6.7) 
15 (10, 20) 
5, 40 
 
16.4 (6.6) 
15 (10, 20) 
5, 40 
Cigarettes per day now  
Mean[SD] 
 Median[1
st
 Q, 3
rd
 Q] 
 Min, max 
 
9.0 (5.9) 
8 (5, 10) 
1, 40 
 
9.4 (6.1) 
10 (5, 10) 
1, 40 
Time to first cigarette after waking 
Within 5 minutes  
6-30 minutes  
31-59 minutes  
1-2 hours  
More than 2 hours 
 
64 (31.5) 
56 (27.6) 
41 (20.2) 
22 (10.8) 
20 (9.9) 
 
64 (31.4) 
61 (29.9) 
31 (15.2) 
29 (14.2) 
19 (9.3) 
Frequency of urges to smoke in the past 24 hours  
Not at all  
A little of the time  
 
3 (1.5) 
36 (17.7) 
 
8 (3.9) 
37 (18.1) 
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Some of the time  
A lot of the time  
Almost all the time  
All the time 
94 (46.3) 
44 (21.7) 
16 (7.9) 
10 (4.9) 
88 (43.1) 
42 (20.6) 
18 (8.8) 
11 (5.4) 
Strength of urges to smoke in the past 24 hours  
No urges  
Slight  
Moderate  
Strong  
Very strong  
Extremely strong  
 
4 (2.0) 
58 (28.6) 
78 (38.4) 
39 (19.2) 
15 (7.4) 
9 (4.4) 
 
6 (2.9) 
55 (27.0) 
95 (46.6) 
28 (13.7) 
14 (6.9) 
6 (2.9) 
Have you set a quit date?  
No  
Yes  
 
193 (95.1) 
10 (4.9) 
 
192 (94.1) 
12 (5.9) 
Are you seriously planning to quit? 
No 
Within the next 3 months 
Within the next 30 days 
Within the next 2 weeks 
 
17 (8.4) 
68 (33.5) 
55 (27.1) 
63 (31.0) 
 
19 (9.3) 
57 (27.9) 
59 (28.9) 
69 (33.8) 
Number of births beyond 24 weeks  
Mean[SD] 
 Median[1
st
 Q, 3
rd
 Q] 
 Min, max 
 
1.4 (1.5) 
1 (0, 2) 
0, 10 
 
1.4 (1.4) 
1 (0, 2) 
0, 9 
Parity  
0 births beyond 24 weeks  
1 or more births beyond 24 weeks 
 
66 (32.5) 
137 (67.5) 
 
65 (31.9) 
139 (68.1) 
Partner/significant other’s smoking status  
Smoker  
Non-smoker  
Not applicable (no partner) 
 
135 (66.5) 
34 (16.8) 
34 (16.8) 
 
128 (62.8) 
44 (21.6) 
32 (15.7) 
Data are N (%) unless specified. 
* Index of Multiple Deprivation, Office for National Statistics. Quintile 1 represents least deprivation 
†Data was complete for all baseline variables other than Index of Multiple Deprivation (IMD) score (3.2% 
missing: no match to home postcode), highest qualification (1.2% missing) and ethnicity (0.25% missing). 
Similar proportions per trial arm were missing baseline data. 
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Table 2 MiQuit treatment effect estimates on seven smoking outcomes 
  
Outcome Measure MiQuit* 
N=203 (%) 
Usual Care* 
N=204 (%) 
Total* 
N=407 (%) 
P value** 
 
Adjusted Odds 
Ratio (95% 
CI)*** 
Abstinence reported 
from 4 weeks post-
randomisation until late 
pregnancy (smoking 
outcome #1) † 
Validated 11 (5.42) 4 (1.96) 15 (3.69) 0.064 2.70 (0.93-
9.35) 
Abstinence reported 
from 4 weeks post-
randomisation until late 
pregnancy (smoking 
outcome #2) † 
Self-report 33 (16.26) 33 (16.18) 66 (16.22) 0.983 1.03 (0.61-
1.75) 
7-day point prevalence 
abstinence at late 
pregnancy (smoking 
outcome #3) 
Self-report 36 (17.73) 28 (13.73) 64 (15.72) 0.267 1.34 (0.79-
2.31) 
7-day point prevalence 
abstinence at late 
pregnancy (smoking 
outcome #4) 
Validated 15 (7.39) 9 (4.41) 24 (5.90) 0.202 1.67 (0.72-
4.03) 
7-day point prevalence 
abstinence at 4 weeks 
post-randomisation  
(smoking outcome #5) 
Self-report 15 (7.39) 7 (3.43) 22 (5.41) 0.077 2.11 (0.89-
5.46) 
7-day point prevalence 
abstinence at both 4 
weeks post-
randomisation and late 
pregnancy 
(smoking outcome #6) 
Self-report 13 (6.40) 4 (1.96) 17 (4.18) 0.025 3.16 (1.14-
10.69) 
7-day point prevalence 
abstinence at both 4 
weeks post-
randomisation and late 
pregnancy 
(smoking outcome #7) 
Validated 8 (3.94) 2 (0.98) 10 (2.46) 0.062 3.28 (0.90-
17.36) 
* All smoking outcomes are calculated out of 407 participants in total (203 MiQuit, 204 usual care). 
Participants lost to follow up or with missing outcome data are assumed to be smoking. 
** Unadjusted, from a chi-squared test using a 2-sided p value (Fisher’s exact test p values were used in the 
case of small expected frequencies). 
*** Model-based, adjusted by site and gestation at randomisation (95% profile confidence intervals reported). 
† Russell Standard criterion (permits no more than 5 cigarettes in total). The criterion for all other smoking 
outcomes was total abstinence (‘not even a puff’). 
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Table 3 Use of NHS and other cessation support during trial period 
Outcome* MiQuit 
(N=124) 
Usual Care 
(N=130) 
Reported use of any stop smoking support N (%) 83 (66.9) 98 (75.4) 
Reported use of different types of support N (%):   
 GP or nurse discussion 20 (16.1) 26 (20.0) 
 Midwife discussion 45 (36.3) 72 (55.4) 
 Stop smoking helpline 5 (4.0) 6 (4.6) 
 NHS Smokefree website 16 (12.9) 15 (11.5) 
 Other smoking cessation website 7 (5.7) 9 (6.9) 
 NRT 26 (21.0) 36 (27.7) 
 Individual NHS behavioural support 9 (7.3) 15 (11.5) 
 Group NHS behavioural support 3 (2.4) 3 (2.3) 
* Outcomes are calculated out of 254 participants with response data at late pregnancy follow up (124 MiQuit, 
130 usual care)  
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Table 4 Intervention participant views of and preferences for the MiQuit intervention 
 MiQuit 
Reported receiving text messages (n=123) 120 (97.6, 93.1-99.2) 
Discontinued the support prematurely by texting ‘STOP’ (n=203) 27 (13.3, 9.3-18.7) 
Rated the text messages as ‘quite’ or ‘extremely’ helpful (n=120) 74 (61.7, 52.7-69.9) 
Rated the text messages as ‘quite or ‘extremely’ annoying (n=120) 17 (14.2, 9.0-21.5) 
Rated the number of text messages received as (n=120):  
 ‘far too many’ or ‘a little too many’ 25 (20.8, 14.4-29.2) 
 ‘about right’ 79 (65.8, 56.8-73.9) 
 ‘not enough’ or ‘not nearly enough’ 16 (13.3, 8.3-20.8) 
Would ‘probably’ or ‘definitely’ recommend the support (n=120) 97 (80.8, 72.8-86.9) 
 
Data are N (%, 95% Wilson CI) 
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Figure 1 Trial flow 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
*Includes 17 MiQuit participants without 4-week follow up data 
**Includes 14 usual care participants without 4-week follow up data 
 
Assessed for eligibility 
(n=1181) 
Excluded (n= 774) 
1. Smokes < 1 per day now 44 
2. Smoked < 5 per day pre-pregnancy 6 
3. In another text service 4 
4. Not able to understand English 8 
5. > 25 weeks gestation 82 
6. Unwilling to consent 14 
7. Not interested in study 363 
8. Other 167 
9. Unknown 86 
 
Randomised  
(n=407) 
Allocated to MiQuit arm  
(n=203) 
Did not complete 4 week FU 
(n=65) 
Lost to follow up (n=61) 
Withdrew consent (n=2) 
Fetal death (n=2) 
 
 
Abstinence data collected at 4-
week follow up  
(n=138) 
Allocated to usual care arm 
(n=204) 
Did not complete 4 week FU 
(n=47) 
Lost to follow up (n=47) 
Withdrew consent (n=0) 
Fetal death (n=0) 
 
 
Abstinence data collected at 4-
week follow up  
(n=157) 
 
Abstinence data collected at 36 weeks 
gestation 
 (n=129)* 
Abstinence data collected at 36 weeks 
gestation 
 (n=132)** 
Did not complete 36-week 
gestation FU (n=26) 
Lost to follow up (n=23) 
Fetal death (n=3) 
 
 
 
Did not complete 36-week 
gestation FU (n=39) 
Lost to follow up (n=34) 
Fetal death (n=3) 
Withdrew consent (n=1) 
Unknown reason (n=1) 
 
 
Analysed 
(n=203) 
Analysed 
(n=204) 
